News

A significantly higher number of patients receiving voclosporin achieved good renal outcome when compared with placebo.

In a late-breaking abstract, investigators assess how pantoprazole 40 mg daily effects long-term kidney function.

In a late-breaking abstract, investigators assess how discontinuation of ACEi or ARBs impact disease progression for advanced CKD.

The study shows vitamin D levels do not necessarily forecast the risk of cardiovascular disease in patients with chronic kidney disease.

In the last 20 years, most were adult studies which indicates a need for pediatric research activity, especially considering the potential that targeted therapies have for treating chronic kidney disease in children.

Approximately 1 out of every 6 patients with COVID-19 had a reduced eGFR.

Females generally have a lower risk of cardiovascular disease compared to males.

Data presented during ASN 2022 shows how heart failure impacts risk factors for renal outcomes of patients with chronic kidney disease.

An analysis of over-the-counter products show not all AMD-targeting supplements match the recommended dosage from the National Institutes of Health.

In this study, the investigators assessed risk factors in patients with DRESS syndrome receiving vancomycin to treat gram-positive infections.

An analysis of serum dupilumab treatment for atopic dermatitis patients suggests a lack of association between either response or adverse effects.

The FDA recently approved a drug treatment for HBV infection for pediatric patients 12 and older with compensated liver disease.

A recent study into autoimmune and metabolic disturbances identified an association between these conditions and vitiligo cases.

Patients with obesity have higher costs and longer hospital stays for IBD.

New data from the International Pediatric Sleep Association (IPSA) Congress 2022 used smart bed technology that revealed consistent findings to previous studies.

Only 7% of trials included a patient-reported outcome measure as a primary outcome measure.

Evaluating the stigma associated with various dermatologic conditions is more accessible with the validated PUSH-D questionnaire.

New cohort analysis data suggest the risk of COVID-19 death is about 38% decreased among patients with the autoimmune disease.

An interview featuring Dr. Rosmarin regarding the recent phase 3 TRuE-V trials on ruxolitinib and nonsegmental vitiligo treatment.

A discussion regarding the main data points from the Phase 3 TRuE-V clinical trial program assessing the use of ruxolitinib cream for nonsegmental vitiligo.

A 1-unit increase in mean weekly SPD scores was linked to a 1.4-times increase in clinic visits for itch among adults aged 65 years or old.

New phase 3 data shared at Fall Clinical Dermatology show the IL-13 inhibitor maintained skin clearance observed at 16 weeks.

After the announced recall of dry shampoo products by Unilever this month, dermatologists anticipate an uptick in patient concerns.

The need for repeat laser peripheral iridotomy was comparable in the study, at 10.0% in the nepafenac group compared to 15.4% in the bromfenac group.

Aside from the inability to fulfill the site inspection, there was no other reason for the FDA deferral. The approval of the combination drug candidate's 2 components are still expected.

New research demonstrated a correlation between specific VDR polymorphisms and patients’ liability of having vitiligo.

Up to 2% of patients with IBD also have EoE.

High IOP variability was independently associated with retinal nerve fiber layer thinning rate in patients with glaucoma.

The Pompe disease community is anticipating the pivotal FDA decision for AT-GAA, a combination therapy for late-onset Pompe disease (LOPD) that has the potential to expand the armamentarium of physicians.

A discussion with the moderator of the Global Parents for Eczema Research symposium regarding climate change and the effects of fire, drought, airborne pollution on atopic dermatitis.